Teva’s Migraine Drug Got CHMP Positive Opinion

Teva’s migraine drug Ajovy (fremanezumab) has moved closer to the EU market after the influential CHMP regulatory committee gave it the green light. The decision paves the way for European approval...

Teva and Neos Agreed upon Patent of ADHD Drug

Teva and Neos Therapeutics have reached a confidential settlement and licensing agreement that resolves a patent dispute over the Israeli firm’s generic version of Neos’ ADHD drug Cotempla XR-ODT (met...

FDA Approved Breast Cancer Drug of Celltrion and Teva

The FDA has approved Celltrion and Teva’s biosimilar of Roche’s breast cancer drug Herceptin, the second potential competitor to the cancer blockbuster in the US. Herceptin is due to go off patent ...

Teva recalls Amlodipine/Valsartan medicines in the USA

Teva Pharmaceuticals has initiated a voluntary recall in the USA due to an impurity detected in an active pharmaceutical ingredient (API) manufactured by Mylan (India).

Teva moves its U.S. headquarters to New Jersey

Teva executives Kåre Schultz and Brendan O’Grady, alongside New Jersey Governor, Phil Murphy, formalized Teva’s commitment to consolidate its North America Commercial business areas into New Jersey .

Teva receives the Klaus Tschira Human Resources Innovation Award

SAP SE, a German-based European multinational software corporation, announced Teva Pharmaceutical Industries as the 2018 recipient of the Klaus Tschira Human Resources Innovation Award.

FDA delays approval of Teva and Celltrion biosimilar drug due to manufacturing issues

fda office
According to a statement on Celltrion’s website, the FDA has requested supplementary information about the products.

Bayer, Novartis and Teva topped February sales rankings in Russia

According to DSM Group, in February 2018, the commercial market of medicinal products amounted to 80.6 billion rubles (in retail prices). Compared to January 2018, the market volume increased by 4.0%.

Teva will receive $700 million from Allergan

Allergan PLC, headquartered in Dublin, Ireland, a global pharmaceutical company, will pay Teva Pharmaceutical Industries Ltd. $700 million to dismiss a dispute between the two companies

Teva undertakes a restructuring process

Teva Pharmaceutical Industries Ltd. announced a new organization and leadership structure aimed to achieve better commercial focus and drive value creation

Teva appointed Kare Schultz as new CEO and Company’s President

Teva Pharmaceutical Industries Ltd. today announced that its Board of Directors has named Kare Schultz to become the Company’s President

Teva has long-term plans for the Russian market

In its financial report for Q2 2017, Teva announced that it was curtailing the activities in 45 countries

EC suspects Teva in EU antitrust rules violation

The European Commission has informed pharmaceutical company Teva of its preliminary view that an agreement concluded with Cephalon was in breach of EU antitrust rules

Teva lost a patent case to GSK and must pay $235 million

A US court yesterday ordered Teva Pharmaceutical Industries Ltd. to pay $235 million compensation to GlaxoSmithKline for violation of the latter's patent

Teva reports positive results for Phase III of migraine drug study

Teva Pharmaceutical Industries Ltd. yesterday announced positive results from a Phase III HALO study of fremanezumab

Teva launched an anti-asthmatic drug onto the Russian market

Teva announced the registration of Cinqaero, a unique innovative drug to treat severe, uncontrolled, eosinophilic asthma in adults.